Clinical value of atezolizumab + bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis.
催眠药
伦瓦提尼
癌症研究
作者
Arndt Vogel,Lorenza Rimassa,Hui-Chuan Sun,Ghassan K. Abou-Alfa,Anthony B. El-Khoueiry,David J. Pinato,Monica Daigl,Javier Sanchez Alvarez,Panos Orfanos,Michael Leibfried,Marie-Hélène Blanchet Zumofen,Vincent E. Gaillard,Philippe Merle
4585Background: The IMbrave150 pivotal study in unresectable HCC showed superiority of atezolizumab + bevacizumab (atezo + bev) vs sorafenib for OS and PFS. Based on these data supporting first-lin...
PDF的下载单位、IP信息已删除
(2025-6-4)
null
无极微光
吃葡萄不吐葡萄皮
Criminology34
学霸业
GingerF
Gp1983
Elsevier大王
My_magnum_opus
sanvva
Chinno
MchemG
v0id
deli
华无剑
李小白
Nole
lx
麦咕咕
EeeeW
皖公网安备34019202002308
